The determine of thyroid stimulating hormone and thyroid hormones changes in thyroid cancer

Abstract

Background: Thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly in world. Serum thyroid stimulating hormone is growth factor for thyrocytes, with prolongod exposure causing nodular growth in the thyroid tissue, thus increasing the risk of thyroid cancer. In our study we aimed for determined serum TSH levels and it’s association with type of cancer, in terms of stage, reccurance of tumor, lymph node involvement and distant metastasis. Method and materials: We have conducted a retrospective review of thyroid cancer from 2014 to 2019 in Head and Neck surgey department of National Cancer Center of Mongolia. Out of 211 patients, 75 cases were included according to inclusion criteria. We noted the histopathological diagnosis and serum TSH level from the medical record. We calculated the stage of tumor through modified American Joint Cancer Committee (AJCC) staging system. Results: The average age of our participants was 46, of which 78% were female. The mean of serum TSH, free T3 and free T4 levels of patients included was 2.48±1.82 µIU/ml, 3.88±1.33 pmol/l, T4 and15.41±3.37 pmol/l respectively. Serum thyroid stimulating hormone levels increased significantly to lymph node metastasis (3.02±2.01 µIU/ml), distant metastasis (4.65±2.71 µIU/ml), and reccurence of cancer (3.25±2.23 µIU/ml). Conclusion: Thyroid function is predominantly euthyroidism of thyroid cancer. Higher TSH level is associated with lymph node metastasis and distant metastasis but not associated with advanced staging.